CPC201

CPC201 is a preclinical-stage small molecule therapeutic being developed by Alephoson for the treatment of ophthalmic conditions, specifically glaucoma and ocular hypertension. The drug utilizes Alephoson's proprietary Cell-Penetrating Complex (CPC) technology, which is a non-covalent, non-cytotoxic delivery platform designed to transport therapeutic payloads across biological barriers such as the cornea and blood-retinal barrier. By employing the CPC platform, CPC201 aims to provide an effective topical (eye drop) alternative to traditional administration routes, enhancing drug penetration and bioavailability within the ocular tissues to reduce intraocular pressure without the need for invasive injections.

Other names

CPC201CPC-201CPC 201